GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

cilgavimab   Click here for help

GtoPdb Ligand ID: 11329

Synonyms: AZD1061 | COV2-2130 | Evusheld® (tixagevimab + cilgavimab)
Approved drug
cilgavimab is an approved drug (EMA (2022))
Compound class: Antibody
Comment: Cilgavimab is a monoclonal antibody against the surface spike protein of SARS-CoV-2 [3]. It was developed by AstraZeneca. This mAb blocks spike binding to ACE2 and prevents infection in animals. It is designed to be a long-acting agent, and in combination with tixagevimab (co-packaged combination= Evusheld®), is proposed as a therapeutic for those people who are likely to respond poorly to SARS-CoV-2 vaccines, or who cannot be vaccinated for any reason, including those who are immunocompromised [1]. Data from the Phase 3 PROVENT trial (NCT04625725) show protection from infection that lasts for at least six months. AstraZeneca have reported that Evusheld® retains neutralising activity against the BA.1 omicron (B.1.1.529) SARS-CoV-2 variant. Cilgavimab as a single agent rmore effectively neutralises the BA.2 omicron subvariant than tixagevimab in vitro [2], so the combination retains neutralising activity.
Classification Click here for help
Compound class Antibody
Approved drug? Yes. EU EMA (2022)
International Nonproprietary Names Click here for help
INN number INN
11777 cilgavimab
Synonyms Click here for help
AZD1061 | COV2-2130 | Evusheld® (tixagevimab + cilgavimab)
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 1106
Other databases
GtoPdb PubChem SID 434321764
Search PubMed clinical trials cilgavimab
Search PubMed titles cilgavimab
Search PubMed titles/abstracts cilgavimab